Gujarat Kidney and Super Speciality IPO – Complete Details, Financials, Strengths, Risks & FAQs
The Gujarat Kidney and Super Speciality IPO is an upcoming public issue by Gujarat Kidney and Super Speciality Limited, a regional healthcare company operating a chain of multi-speciality hospitals in Gujarat. The company primarily focuses on renal sciences, while also offering a wide range of secondary and tertiary healthcare services.
This IPO provides investors an opportunity to participate in the healthcare sector, which is considered a long-term growth industry due to increasing demand for quality medical services in India.
About Gujarat Kidney and Super Speciality Limited
Gujarat Kidney and Super Speciality Limited operates as a regional chain of mid-sized multi-speciality hospitals located in central Gujarat. The company manages seven hospitals and focuses on providing specialized treatments in renal sciences along with other medical disciplines.
Key Business Highlights:
-
Strong focus on urology, nephrology, dialysis, kidney transplant, and uro-oncology
-
Expansion into laparoscopic and robotic surgeries
-
Gradual entry into cardiology (both interventional and non-interventional)
-
Presence in cities such as Vadodara, Godhra, Dahod, Bharuch, and Padra
-
Operates through hospitals like Sanjay Gandhi Hospital, Madhav Hospital, and Harmony Medicare
Company Details:
-
Founded: 2019
-
MD & CEO: Dr. Pragnesh Yashwansinh Bharpoda
-
Parent Organization: Gujarat Kidney & Super Speciality Ltd
Gujarat Kidney and Super Speciality IPO Details
| Particulars | Details |
|---|---|
| IPO Opening Date | 22 December 2025 |
| IPO Closing Date | 24 December 2025 |
| Tentative Allotment Date | 26 December 2025 |
| Tentative Listing Date | 30 December 2025 |
| Issue Size | ₹250.80 Crore |
| Price Band | ₹108 – ₹114 per share |
| Face Value | ₹2 per share |
| Lot Size | 128 shares |
| Minimum Investment | ₹13,824 |
| Issue Type | Book Built Issue |
| Listing At | BSE and NSE |
| Registrar | LINK Intime |
IPO Application Details
For Retail Investors:
-
Price Band: ₹108 – ₹114
-
Lot Size: 128 shares
-
Minimum Order Quantity: 1 lot (128 shares)
-
Application Amount: ₹13,824 (at upper price band)
For High Net-Worth Individuals (HNI):
-
Application Range: ₹2 Lakh – ₹5 Lakh
-
Lot Size: 128 shares
Eligible investors can apply under the Retail or HNI category as per SEBI norms.
Gujarat Kidney and Super Speciality Financial Performance
(All figures are in ₹ Crore)
Revenue Growth:
-
FY 2023: ₹0.00
-
FY 2024: ₹4.77
-
FY 2025: ₹42.24
The company has shown sharp revenue growth, indicating rapid operational scaling and increased patient inflow across its hospitals.
Profit Performance:
The financial graph in the IPO document indicates a significant improvement in profitability, especially in FY 2025, reflecting better capacity utilization and operational efficiency.
Strengths of Gujarat Kidney and Super Speciality IPO
-
Strong Focus on Renal Sciences
The company has developed a strong franchise in renal sciences, supported by multiple sub-specialities like urology, nephrology, dialysis, renal transplant, and uro-oncology. -
Expanding Medical Infrastructure
It has expanded into advanced laparoscopic and robotic surgeries and established dedicated laparoscopic departments across hospitals. -
Geographic Presence in Central Gujarat
The company operates hospitals in underserved cities, benefiting from lower competition and rising healthcare demand. -
Experienced Medical Professionals
Gujarat Kidney claims to attract and retain skilled doctors with low attrition rates. As of June 30, 2025, its medical team included doctors, nurses, and paramedical staff supported by structured compensation models. -
Revenue Diversification
Apart from renal care, the company is gradually expanding into cardiology and other non-renal specialities, improving revenue stability.
Risks and Concerns of the IPO
-
Limited Operating History
The company has a relatively short operating history in its current form, making long-term performance assessment difficult. -
Greenfield Project Execution Risk
The company has limited experience in executing greenfield hospital projects, which may impact future expansion plans. -
High Dependency on Gujarat Region
Most hospitals are located in Gujarat, exposing the business to regional risks such as regulatory changes or local competition. -
High Receivables
As of June 30, 2025, trade receivables were ₹21.39 crore, forming a significant portion of revenue. Delays in collection may impact cash flows. -
Rising Costs and Occupancy Risks
Bed occupancy rates and operational efficiency need to improve consistently to sustain profitability. -
Legal Proceedings
The company and its promoters are involved in certain legal proceedings, which could impact business operations if adverse outcomes arise. -
Outstanding Financial Liabilities
As of September 30, 2025, the company had outstanding financial indebtedness of ₹15.35 crore.
Key IPO FAQs
What is the issue size of Gujarat Kidney and Super Speciality IPO?
The issue size of the IPO is ₹250.80 crore.
What are the IPO opening and closing dates?
The IPO opens on 22 December 2025 and closes on 24 December 2025.
What is the lot size and minimum order quantity?
The lot size is 128 shares, and the minimum order quantity is 1 lot.
What is the allotment date?
The tentative allotment date is 26 December 2025.
When will the IPO be listed?
The shares are expected to be listed on 30 December 2025.
Where will the IPO be listed?
The IPO will be listed on both BSE and NSE.
Who is the registrar of the IPO?
The registrar is LINK Intime.
Conclusion
The Gujarat Kidney and Super Speciality IPO presents an opportunity to invest in a growing regional healthcare company with a strong focus on renal sciences and expanding hospital infrastructure. While the company has shown impressive revenue growth, investors should carefully evaluate risks such as regional concentration, receivables management, and limited operating history.
This IPO may be suitable for investors with a medium-to-long-term horizon who understand the healthcare sector dynamics and associated risks.
Disclaimer
This article is for educational and informational purposes only and does not constitute investment advice. IPO investments are subject to market risks. Investors are advised to read the Red Herring Prospectus (RHP) carefully and consult with a certified financial advisor before making any investment decision. The author and publisher are not responsible for any financial losses arising from investments based on this information.
Comments
Post a Comment